| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -8,275 | -40,371 | -38,000 | -468,005 |
| Depreciation | 2,200 | 2,736 | 2,461 | 7,790 |
| Amortization of intangible assets | 1,020 | 1,019 | 1,020 | 367,409 |
| Amortization of right-of-use assets | 849 | 894 | 921 | 2,162 |
| Share-based compensation expense | 4,459 | 9,588 | 10,984 | 21,096 |
| Impairment charges | 0 | 0 | 0 | 15,000 |
| Merger-related compensation expense | NaN | 0 | NaN | NaN |
| Loss on extinguishment of debt | NaN | 0 | NaN | NaN |
| Gain on debt restructuring | NaN | 0 | NaN | NaN |
| Gain on disposal of assets | 48,100 | NaN | NaN | NaN |
| Accretion of discount and amortization of premium on marketable securities, net | 295 | 460 | 923 | 2,982 |
| Change in the estimated fair value of contingent consideration | 0 | 0 | 0 | -18,700 |
| Inventory provision | 54 | -200 | 1,226 | 8,542 |
| Deferred income taxes | 0 | 0 | 0 | -546 |
| Other | -225 | -232 | -397 | -1,059 |
| Accounts receivable, net | -6,098 | 4,832 | -1,641 | 4,733 |
| Inventory, net | 3,206 | -3,507 | 1,058 | 3,868 |
| Prepaid expenses and other assets | 2,288 | -717 | -988 | -6,809 |
| Accounts payable | -4,322 | 1,721 | 1,266 | -505 |
| Accrued expenses | 314 | 4,554 | 1,011 | -2,407 |
| Deferred revenue | 19 | -584 | -123 | 808 |
| Operating lease liabilities | 1,425 | 1,384 | 1,069 | -1,730 |
| Contingent consideration liability | NaN | 0 | NaN | NaN |
| Other liabilities | 5,132 | 1,026 | -1,587 | -632 |
| Net cash used in operating activities | -44,691 | -19,069 | -18,707 | -73,433 |
| Proceeds from disposal of assets | 50,000 | NaN | NaN | NaN |
| Payment for waiver of milestone obligation | 1,900 | NaN | NaN | NaN |
| Purchases of property and equipment | 3,043 | 861 | -86 | 1,939 |
| Purchases of intangible assets | 5,000 | 0 | 0 | 5,000 |
| Cash paid for purchases of acquired entities, net of cash acquired | NaN | 0 | NaN | NaN |
| Purchases of investments | 52,448 | 33,094 | 65,825 | 117,992 |
| Sales of investments | NaN | 0 | 0 | NaN |
| Payment of debt issuance costs | NaN | 0 | NaN | NaN |
| Maturities of investments | 48,250 | 59,984 | 84,641 | 195,448 |
| Payment of contingent consideration | NaN | 0 | NaN | NaN |
| Net cash provided by investing activities | 35,859 | 26,029 | 18,902 | 70,517 |
| Payments made in conjunction with convertible notes exchange | NaN | 0 | NaN | NaN |
| Notes payable principal payoff | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock under equity offerings, net of issuance costs | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock from equity plans | 1,437 | 0 | 1,469 | 1,959 |
| Net cash provided by financing activities | 1,437 | 0 | 1,469 | 1,959 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -7,395 | 6,960 | 1,664 | -957 |
| Cash, cash equivalents, and restricted cash at beginning of period | 65,259 | 58,299 | 57,592 | NaN |
| Cash, cash equivalents, and restricted cash at end of period | 57,864 | 65,259 | 58,299 | NaN |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)